《半新股異動》鳳祥(09977.HK)急漲27%破頂成交急增
山東鳳祥股分(09977.HK)雖然在8月7日公布,全球發售穩定價格期於7月6日結束,超額配售權並未獲行使並於同日失效。但該股連升第六天,尤其是今天升破首掛日所造上市高位3.59元後,買盤持續跟進,最高見4.46元,現造4.33元,急漲27%,成交急增至6,557萬股(僅次於首掛日7,082萬股),涉資2.75億元。
根據弗若斯特沙利文報告,就2019年商品肉雞的產量而言,山東鳳祥是內地第二大全面一體化白羽肉雞生產商。股份於7月16日以每股3.33元來港上市,淨籌逾10億元。股價於首掛日高見3.59元遇阻,之後於至2.87至3.54元之間反覆爭持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.